Solifenacin (Bispec (5 mg)) is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence.It works by blocking the action of certain chemicals in the body to help ...

This medication is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence.

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Advisory Alert: It has come to our attention ...

NEW DELHI: Glenmark Pharmaceuticals today said the US health regulator has granted tentative approval for tablets used for treatment of overactive bladder. The company has been granted tentative ...

Shares of pharma major Glenmark Pharma rose as much as 2.5 percent intraday Thursday as it has received tentative USFDA nod for Solifenacin Succinate tablets. "Glenmark Pharmaceuticals Inc., USA has ...

Astellas Pharma announced results from the Phase 3b BESIDE trial of solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy in incontinent overactive bladder (OAB) patients. The BESIDE study is ...

Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg," the ...

Glenmark Pharmaceuticals received final approval from the United States (US) health regulator for Solifenacin Succinate tablets, used for treatment of overactive bladder, on Tuesday. The approved ...

Glenmark Pharmaceuticals today said the US health regulator has granted tentative approval for tablets used for treatment of overactive bladder. “We have been granted tentative approval by the United ...

New Delhi, Jun 22 (PTI) Glenmark Pharmaceuticals today said the US health regulator has granted tentative approval for tablets used for treatment of overactive bladder. The company has been granted ...